A Phase 1 interventional study of sitagliptin and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 178th largest by enrollment of the 197 interventional ones that give a count, is one of 12 that started in 2009, is one of 23 in phase 1, and was the 69th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 12 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 162nd largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 55 in phase 1, and was the 78th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of a single dose of sitagliptin on glucose dependent insulin secretion using a meal tolerance test (MTT) during a hyperglycemic clamp (HCG) procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
Drug: sitagliptin · Drug: Comparator: Placebo
Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
Drug: sitagliptin · Drug: Comparator: Placebo
Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
Drug: sitagliptin · Drug: Comparator: Placebo
Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
Also known as: sitagliptin phosphate, MK0431
Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose
ISR was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters.
Time frame: 190 minutes to 340 minutes
Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose
Glucose Infusion Rate required to maintain the target glucose level of 160 milligrams / deciliter (mg/dL) ; GIR was normalized to subject's body weight (kg).
Time frame: 190 minutes to 340 minutes
Subjects were recruited at Veeda Clinical Research Pvt. Ltd. in May 2009. First Patient Screened: 20-May-2009. Last Patient, Last Visit: 21-Jul-2009. 1 site
| Milestone | Sitagliptin / Sitagliptin / Placebo | Sitagliptin / Placebo / Sitagliptin | Placebo / Sitagliptin / Sitagliptin |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sitagliptin / Sitagliptin / Placebo | Sitagliptin / Placebo / Sitagliptin | Placebo / Sitagliptin / Sitagliptin |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sitagliptin / Sitagliptin / Placebo | Sitagliptin / Placebo / Sitagliptin | Placebo / Sitagliptin / Sitagliptin |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
| Milestone | Sitagliptin / Sitagliptin / Placebo | Sitagliptin / Placebo / Sitagliptin | Placebo / Sitagliptin / Sitagliptin |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Sitagliptin / Sitagliptin / Placebo | Sitagliptin / Placebo / Sitagliptin | Placebo / Sitagliptin / Sitagliptin |
|---|---|---|---|
| Started | 4 | 4 | 3 |
| Completed | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 |
ISR was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters.
| ng/min | Sitagliptin 100 mg | Placebo |
|---|---|---|
| Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose | 9.73 ± 2.72 | 8.03 ± 2.58 |
Glucose Infusion Rate required to maintain the target glucose level of 160 milligrams / deciliter (mg/dL) ; GIR was normalized to subject's body weight (kg).
| mg / kg / min | Sitagliptin 100 mg | Placebo |
|---|---|---|
| Glucose Infusion Rate (GIR) During 190 - 340 Minutes Post-dose | 15.0 ± 2.6 | 13.7 ± 2.3 |
Collected over Adverse experiences were collected from the time the consent was signed through the 14 day follow up period, after all treatment periods were completed.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | 0/12 (0%) | 1/12 (8.3%) |
| Placebo | — | 0/12 (0%) | 0/12 (0%) |
| Event | Sitagliptin 100 mg | Placebo |
|---|---|---|
| BlisterSkin and subcutaneous tissue disorders | 1/12 | 0/12 |
| Age, Continuous(years) | All Patients |
|---|---|
| Mean | 26.8 ± 6.4 |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 0 |
| Male | 12 |
| Body Mass Index(kg/m2) | All Patients |
|---|---|
| Mean | 20.5 ± 1.3 |
No study locations are listed for this record.
Ran from May 2009 to primary completion in Jun 2009, 0 months.
Results were first posted in Aug 2010, 1 year 1 month after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin